Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002532 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1HPGDGAALMNA | |
| SCHEMBL2091236 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1GAALMNANPC1 | |
| SCHEMBL14817806 | 0.86 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1HPGDGAALMNA | |
| SCHEMBL2091233 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL4304855 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1GAAKDM4ENPC1 | |
| SCHEMBL19462360 | 0.83 | HDAC1 (0.73) | SMN1; SMN2ALDH1A1HPGDHDAC1NPC1 | |
| SCHEMBL1430696 | 0.82 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1HPGDGAALMNA | |
| SCHEMBL30368335 | 0.82 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1HPGDGAALMNA | |
| SCHEMBL30368339 | 0.82 | HDAC1 (0.49) | SMN1; SMN2ALDH1A1HPGDGAALMNA | |
| SCHEMBL11307107 | 0.82 | LMNA (0.53) | SMN1; SMN2ALDH1A1HPGDGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101870653-B | Synthesis method of 2 - methyl -3 - fluoride - 6 -nitrobenzoic acid | SHANGHAI HEQUAN PHARMACEUTICAL CO LTD | 2013-07-10 | — | — | CN | claimed |
| CN-101870653-A | Synthesis method of 2 - methyl -3 - fluoride - 6 -nitrobenzoic acid | SHANGHAI HEQUAN PHARMACEUTICAL CO LTD | 2010-10-27 | — | — | CN | claimed |
| CN-120091815-A | T-type voltage-gated calcium channel enhancer | 广泛研究所股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| CN-101870653-B | Synthesis method of 2 - methyl -3 - fluoride - 6 -nitrobenzoic acid | SHANGHAI HEQUAN PHARMACEUTICAL CO LTD | 2013-07-10 | — | — | CN | disclosed |
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20040157852-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6656940-B2 | Treatment of cancer. | SUGEN, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| US-20020055511-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | SUGEN, INC. | 2002-05-09 | — | — | US | disclosed |
| US-6329375-B1 | ENZYME INHIBITORS AND ANTIINFLAMMATORY AGENTS | SUGEN, INC. | 2001-12-11 | — | — | US | disclosed |
| WO-1999007701-A1 | TRICYCLIC QUINOXALINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | SUGEN, INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1992021668-A1 | BENZOTHIAZEPINONES AND THEIR USE AS ANTICONVULSANTS | THE BOOTS COMPANY PLC (GB) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055511-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | PDXK, TK1, ABL1 | SMN1; SMN2 4768/4885ALDH1A1 3484/4885HPGD 646/4885 |
| US-20040157852-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | PDXK, TK1, ABL1 | SMN1; SMN2 4768/4885ALDH1A1 3484/4885HPGD 646/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | SMN1; SMN2 2958/4885ALDH1A1 618/4885HPGD 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.